- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
KDIGO Clinical Practice Guideline for the Evaluation, Management, & Treatment of ADPKD (Part 1)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
KDIGO Clinical Practice Guideline for the Evaluation, Management, & Treatment of ADPKD (Part 1)
Background
- ADPKD is the most prevalent monogenic kidney disease associated with kidney failure1
- An estimated 50% of patients with ADPKD will reach kidney failure by the time they are 60 years old1
- Until recently, there have been no standardized guidelines for the diagnosis and management of patients with ADPKD
- KDIGO convened a panel of multidisciplinary experts to develop clinical practice guidelines to capture their recommendations
- The goal of this webinar series is to review the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD
- Understand the level of evidence and interpret the KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD
- Explore the different chapters in the KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD, including but not limited to, diagnosis and prognosis, management of renal and extrarenal manifestations, and general approaches to management of ADPKD
- ADPKD, autosomal dominant polycystic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes. KDIGO. Kidney Int. 2025;107(2S):S1–S239.
Speaker
Frederic F Rahbari Oskoui, MD
Professor of Medicine, Nephrology, Emory University School of MedicineEmory University School of Medicine*
Dr Frederic Rahbari is the director of Cystic Kidney Diseases Clinic at Emory University and has been a nephrologist practicing at Emory University Hospital in Atlanta, GA since 2006. Dr Rahbari attended medical school at Université de Bordeaux in France and completed a residency program at the same institution. After moving to the United States, Dr Rahbari did clinical and translational research on oxidative stress at New York Medical College and subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons. He has also completed a fellowship in nephrology at Emory University. Dr Rahbari has been a principal investigator in several PKD trials and is a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation.
Moderator
Hannah N. Lambert, PharmD
Nephrology Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*Hannah N. Lambert is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. She earned her Doctor of Pharmacy and completed her clinical residency training at Xavier University of Louisiana College of Pharmacy in New Orleans, LA. Prior to joining Otsuka, Dr Lambert was a clinical pharmacist at Ochsner Health in Digital Medicine.
Frederic F. Rahbari Oskoui is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Hannah Lambert is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
September 2025 US.CORP.X.25.00190Registration
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
